Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, and Etoposide in patients with Hodgkin Lymphoma.

Statements

Source and description
Adcetris (brentuximab vedotin) [product information]. EMA. The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) for the treatment of adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III, or Stage IV Hodgkin lymphoma (HL).